Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. (linkinghub.elsevier.com)

Authors: Nauck MA … Bluher M Journal: The Lancet Published: 2026-02-28 DOI: https://doi.org/10.1016/S0140-6736(25)02105-1